Wellington Partners is a leading European venture capital firm supporting outstanding entrepreneurs and their products on their way to market leadership. We have already invested in more than 50 early- and growth-stage life science companies, active in the fields of biotechnology, therapeutics, medical devices, diagnostics and digital health. We do not only provide financial resources, but also contribute our expertise, hard work and passion to help world class teams in building successful businesses of exceptional growth. Working hand in hand with our portfolio companies, we turn big ideas into big successes.
We provide world class entrepreneurs with the capital for the financing of breakthrough products with the potential to decisively improve current standard of care and, most importantly, the lives of patients. We proactively source deals and lead or co-lead financing rounds, from early stage to expansion stage and selected PIPE investments (Private Investment in Public Equity). Our ticket sizes typically range from EUR 2 million to EUR 20 million.
All-round support forall stages of growth
Providing funding is only one part of our business, with long-term commitment and active collaboration being the other. Our team consists of both MDs and PhDs and brings together a unique combination of passionate and committed people, extensive investment experience and company-building skills. Our role is to offer board level strategic support to entrepreneurs while they exercise operational control. Together with our global scientific and commercial network, we are in a position to organize financing rounds, accelerate preclinical and clinical development, regulatory approval processes, and drive successful market entry into the most important healthcare markets in Europe, the U.S. and Asia.
"Wellington Partners has been a formative investor and provided us with access to an invaluable investor network and key contacts throughout the pharmaceutical industry. Their continued commitment provides us with a strong foundation as we continue enhancing our GPCR-focused platform and advance our multi-indication pipeline.”
— Dr. Cedric Ververken – CEO of Confo Therapeutics
“We are grateful for the support of Wellington Partners as our lead investor. The team have been supporting our company for few years now, through significant investments, and a deep understanding of our technology and business opportunity. Their broad network in the healthcare industry is also a key strength for us.”
— Dr. Hamid Lamraoui – CEO of UroMems
“Rainer and the Wellington team have deep experience of healthcare markets and what it takes to achieve success. They bring creative suggestions to difficult strategic questions, and an active voice to reaching the best answers”
— Dr. Oliver Harrison – CEO of Koa Health
“Wellington Partners joined as investors in MinervaX late 2020. They have provided constructive and very enthusiastic support ever since through a strong knowledge and in-depth understanding of the Field”
— Dr. Per Fischer – CEO of Minervax
“We are delighted to have Wellington as our partner. From day one, they have challenged and helped building our business plans. Now, they support and guide our execution and continuously enable us to move forward.”
— Frank Gehres – CEO of Creative Balloons
“We are grateful for Regina’s commitment to ONWARD and her support in completing the largest early stage medtech IPO in European history.”
— Dave Marver – CEO of Onward Medical
“Wellington Partners have been great partners for us and incredibly value-adding for our business, with their team's impressive experience and network in our space.”
— Dr. Tryggvi Thorgeirsson – CEO of Sidekick Health
“WP is an invaluable counselor to and partner in Carisma’s continued growth. We are grateful for their guidance, support, and leadership.”
— Steven Kelly – CEO of Carisma Therapeutics
“Wellington Partners plays an essential role in our journey to becoming the leading CRISPR-technology, gene therapy and microbiome company, developing breakthrough therapies advancing human health.”
— Dr. Christian Grøndahl – CEO of SNIPR Biome
“At eGenesis, we are developing human-compatible organs and cells for patients who need a transplant. Wellington has been an invaluable partner in our bold mission to solve the organ shortage crisis. We have relied on their savvy expertise and steadfast financial support as we work toward the day that no one dies while waiting for a transplant.”
— Paul Sekhri – former CEO of eGenesis
“I’ve been privileged to work with Wellington both as a co-investor and a portfolio company. The team at Wellington is smart, knowledgeable, and great to work with. As a committed partner for the journey, Wellington has consistently been there to support Quanta, from our Series A round through to our Series D growth funding. Along the way, they have provided strategic insight, guidance, and advice and have been generous with their broad network of contacts. Wellington is a world-class venture fund with a European flair and a global perspective.”
— John E Milad – CEO of Quanta Dialysis Technologies
“The Wellington Team are very engaged and highly supportive investors. Their deep sector knowledge and experience in our field of innate immunity have proven invaluable in creating value for us.”
— Dr. Claus Elsborg Olesen – CEO of Stipe Therapeutics
“We enjoy the productive and pleasant exchange with the Wellington Partners team. They have a deep understanding of the subject matter and the specifics of developing an innovative medical device.”
— Helmut Straubinger – CEO of Tricares
“Wellington is a very well experienced VC with a truly global network in the healthcare industry, I have gotten to know some of the smartest brains and leaders in the industry via Rainer Strohmenger and his partners. Rainer, a physician by education, understood the potential of Amboss early on and has ever since supported us in expanding our business from Germany to the US and beyond. Today Amboss empowers millions of doctors worldwide to provide the best possible care. Thanks a lot to Wellington for their pioneering support on this bold mission!”
— Dr. Madjid Salimi – CEO of AMBOSS
“At Adrenomed we understand the importance of having a long standing, dedicated, and committed leading Venture Capital firm like Wellington Partners who share the same vision and passion. Their overarching premise to ‘Think Bigger’ is demonstrated by their desire to work with Adrenomed, taking on solving a big unmet medical need that directly impacts millions of people worldwide and which has been historically viewed as clinically challenging. The team at Wellington Partners are deeply involved, working hand in glove with the Supervisory and Management Board, helping us to work through various challenges and identify opportunities that will enable us to achieve our longer term business goals and objectives. Wellington Partners are not just investors but are true Partners which in the biotech sector is truly unique.”
— Dr. Richard Jones – CEO of Adrenomed
